| Literature DB >> 23663499 |
Kung-Hao Liang1, Chau-Ting Yeh.
Abstract
BACKGROUND: Alus are primate-specific retrotransposons which account for 10.6% of the human genome. A large number of protein-coding mRNAs are encoded with sense or antisense Alus in the un-translated regions.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23663499 PMCID: PMC3655826 DOI: 10.1186/1471-2164-14-325
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Two genes with Alu sense or antisense elements in the 3′UTR
| antisense | NM_022817.2 | 5318-5631 | 314 | 4005-6342 | 3856-6342 | 52.9 | |
| sense | NM_006197.3 | 7691-8008 | 318 | 6497-8788 | 6472-8783 | 52.8 |
Figure 1Secondary structures of and mRNAs predicted by a co-folding algorithm. (A) The co-folding of full length mRNAs of PER2 (Green) and PCM1 (Red). A long line of duplex structure was observed. (B) A focused view of the duplex caused by the antisense base pairing of Alus on PER2 (Green) and PCM1 (Red).
List of all pathways where Sens-alus and Ant-alus are enriched or depleted
| | | |
| p53 pathway | 0.2470 | |
| Opioid prodynorphin pathway | 0.6090 | |
| Muscarinic acetylcholine receptor 2 and 4 signaling pathway | 0.2270 | |
| Pyridoxal phosphate salvage pathway | 0.9260 | |
| Vitamin B6 metabolism | 0.8910 | |
| Metabotropic glutamate receptor group II pathway | 0.5520 | |
| 5HT1 type receptor mediated signaling pathway | 0.2930 | |
| Opioid proopiomelanocortin pathway | 0.4040 | |
| Opioid proenkephalin pathway | 0.4040 | |
| Endogenous_cannabinoid_signaling | 0.3670 | |
| GABA-B_receptor_II_signaling | 0.4560 | |
| Metabotropic glutamate receptor group III pathway | 0.5340 | |
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | 0.3270 | |
| Beta3 adrenergic receptor signaling pathway | 0.3220 | |
| Cortocotropin releasing factor receptor signaling pathway | 0.3770 | |
| 5HT4 type receptor mediated signaling pathway | 0.1540 | |
| Synaptic_vesicle_trafficking | 0.5960 | |
| p53 pathway feedback loops 2 | 0.1580 | |
| Angiotensin II-stimulated signaling through G proteins and beta-arrestin | 0.5690 | |
| | | |
| Huntington disease | 0.3950 | |
| | | |
| Toll receptor signaling pathway | 0.6120 | |
| DPP_signaling_pathway | 0.5960 | |
| Nicotinic acetylcholine receptor signaling pathway | 0.2970 | |
| Gamma-aminobutyric acid synthesis | 0.8130 | |
| SCW_signaling_pathway | 0.4430 | |
| BMP_signaling_pathway-drosophila | 0.4430 | |
| Interleukin signaling pathway | 0.5740 | |
| Endothelin signaling pathway | 0.3140 | |
| DPP-SCW_signaling_pathway | 0.5150 |
†The accompanying False Discover Rate < 25%.
The P values were nominal values without being corrected for multiple comparisons.
List of all biological processes where Ant-alus and Sens-alus are either enriched or depleted
| | | |
| exocytosis | 0.0807 | |
| synaptic vesicle exocytosis | 0.0333 | |
| neurotransmitter secretion | 0.1060 | |
| polysaccharide metabolic process | 0.4470 | |
| organelle organization | 0.3170 | |
| establishment or maintenance of chromatin architecture | 0.3100 | |
| mammary gland development | 0.0841 | |
| glycogen metabolic process | 0.5300 | |
| protein targeting | 0.4670 | |
| dorsal/ventral axis specification | 0.2970 | |
| vitamin catabolic process | 0.9620 | |
| catabolic process | 0.9620 | |
| cellular amino acid catabolic process | 0.5430 | |
| | | |
| anion transport | 0.4800 | |
| visual perception | 0.5310 | |
| developmental process | 0.1630 | |
| nerve-nerve synaptic transmission | 0.3080 | |
| neuromuscular synaptic transmission | 0.5010 | |
| sensory perception | 0.4540 | |
| response to toxin | 0.5300 | |
| response to stimulus | 0.2500 | |
| cell motion | 0.2520 | |
| cell-cell adhesion | 0.3020 | |
| | | |
| cyclic nucleotide metabolic process | 0.5180 | |
| termination of RNA polymerase II transcription | 0.5570 | |
| response to interferon-gamma | 0.3500 | |
| meiosis | 0.2210 | |
| cytokine-mediated signaling pathway | 0.3820 | |
| RNA localization | 0.2320 | |
| | | |
| ectoderm development | 0.1360 | |
| mRNA 3′-end processing | 0.2320 | |
| mRNA polyadenylation | 0.2200 | |
| synaptic transmission | 0.1390 | |
| macrophage activation | 0.4460 | |
| cellular glucose homeostasis | 0.0732 | |
| embryonic development | 0.4190 | |
| defense response to bacterium | 0.0749 |
†The accompanying False Discover Rate < 25%.
The P values were nominal values without being corrected for multiple comparisons.
Comparison of immune-related genes in Ant-alus and Sens-alus
| | ||||
|---|---|---|---|---|
| V(D)J recombination | | | NM_001033855.1 | |
| Toll like receptors | | | NM_006068.3 | |
| | | | NM_016562.3 | |
| | | | NM_030956.2 | |
| Interferon related | | | NM_002198.2 | |
| | | | NM_001031683.2; NM_001549.4 | |
| Cytokines | NM_000641.2 | NM_000877.2 | ||
| | NM_170743.2; | NM_000417.2 | ||
| | | NM_173064.1; | | |
| | | NM_173065.1 | | |
| | NM_207585.1 | NM_000565.2 ; NM_181359.1 | ||
| | | | NM_000628.3 | |
| | | | NM_000628.3 | |
| | | | NM_001560.2 | |
| | | | NM_014339.4 | |
| | | | NM_001562.2 | |
| | | | NM_144701.2 | |
| | | | NM_006140.4; | |
| | | | | NM_172245.2; |
| | | | | NM_172246.2; |
| | | | | NM_172247.2; |
| | | | | NM_172249.2; |
| | | | | NM_001161529.1; |
| | | | | NM_001161530.1; |
| | | | | NM_001161532.1; |
| Chemokines | NM_002990.3 | NM_002985.2 | ||
| | NM_022059.2 | NM_031409.3; | ||
| | | | | NM_004367.5 |
| Cluster of differentiation | NM_013230.2 | NM_006139.2 | ||
| | NM_014880.4 | NM_001001548.2 | ||
| | | | NM_002231.3; | |
| | | | | NM_001024844.1 |
| | | | NM_003874.2 | |
| | | | NM_198196.2 ; | |
| | | | | NM_005816.4 |
| | | | NM_133493.3; | |
| | | | | NM_001159587.1; |
| | | | | NM_001159588.1 |
| | | | NM_052931.3 | |
| | | | NM_021181.3 | |
| HLA and related receptors | NM_133279.2 | NM_002119.3 | ||
| | NM_021642.3; | NM_005516.4 | ||
| | | NM_001136219.1 | | |
| | | | NM_006669.3; | |
| | | | | NM_001081637.1; |
| | | | | NM_001081638.1; |
| | | | | NM_001081639.1 |
| | | | NM_001081450.1; | |
| | | | | NM_006864.2; |
| Transcription factors | | | NM_173164.1 | |
| | | | NM_032815.3 | |
| | | | NM_001001716.1 | |
| | | | NM_013432.4 | |
| | | | NM_001001349.2; | |
| | | | | NM_017595.5; |
| | | | | NM_001144927.1; |
| | | | | NM_001144928.1; |
| | | | | NM_001144929.1 |
| Others | NM_178844.2 | NM_006197.3 | ||
| NM_175066.3 | ||||
List of embryonic stem cell related genes in Ant-alus and Sens-alus
| | | |
| NM_144567.3 | Protein angel homolog 2 | |
| NM_012117.2; NM_001127321.1; NM_001127322.1 | Chromobox protein homolog 5 | |
| NM_013230.2 | Signal transducer CD24 | |
| NM_001254.3 | Cell division control protein 6 homolog | |
| NM_004360.3 | cadherin 1, type 1, E-cadherin (epithelial) | |
| NM_017424.2; NM_177405.1 | Cat eye syndrome critical region protein 1 | |
| NM_000791.3 | dihydrofolate reductase | |
| NM_018189.3 | Developmental pluripotency-associated protein 4 | |
| NM_001025780.1 | Abhydrolase domain-containing protein FAM108B1 | |
| NM_024312.3 | N-acetylglucosamine-1-phosphotransferase subunit beta | |
| NM_005931.3 | MHC class I polypeptide-related sequence B | |
| NM_024865.2 | Homeobox protein NANOG | |
| NM_018283.1 | Probable 7,8-dihydro-8-oxoguanine triphosphatase NUDT15 | |
| NM_002610.3 | 3-phosphoinositide-dependent protein kinase 1 | |
| NM_012393. | Phosphoribosylformylglycinamidine synthase | |
| NM_024900.3 | Protein Jade-1 | |
| NM_001142285.1 | ribosomal protein S24 | |
| NM_001034.3; NM_001165931.1 | Ribonucleoside-diphosphate reductase subunit M2 | |
| NM_016052.3; | RRP15-like protein | |
| NM_006924.4; NM_001078166.1 | Splicing factor, arginine/serine-rich 1 | |
| NM_003212.2 | Teratocarcinoma-derived growth factor 1 | |
| NM_003218.3; NM_017489.2 | Telomeric repeat-binding factor 1 | |
| | | |
| NM_000702.3 | Sodium/potassium-transporting ATPase subunit alpha-2 | |
| NM_030928.3 | DNA replication factor Cdt1 | |
| NM_001943.3 | Desmoglein-2 | |
| NM_024674.4 | Lin-28 homolog A | |
| NM_005914.2; NM_182746.1 | DNA replication licensing factor MCM4 | |
| NM_015341.3 | Condensin complex subunit 2 | |
| NM_006166.3 | Nuclear transcription factor Y subunit beta | |
| NM_006452.3; NM_001079524.1; NM_001079525.1 | Phosphoribosylaminoimidazole carboxylase | |
| NM_016518.2 | Peroxisomal sarcosine oxidase | |
| NM_177968.2 | Protein phosphatase 1B | |
| NM_024504.2 | PR domain zinc finger protein 14 | |
| NM_005044.3 | Serine/threonine-protein kinase PRKX |
Figure 2Expression levels of Sens-alus and Ant-alus upon Alu perturbations. (A) An overview plot of Sens-alus, Ant-alus and genome-wide RNA levels across 6 different treatment conditions. HEK293 cells were transfected with (1) empty pDR2 vectors (pDR2; Hygromycin added); (2) antisense Alus with Hygromycin selection (pDR2-anti-Alu; Hygromycin added; week 0); (3) the same as (2) with Hygromycin removed subsequently (pDR2-anti-Alu; Hygromycin added→removed; week 1); (4) sense Alus with Hygromycin selection (pDR2-sense-Alu; Hygromycin added; week 0); (5) the same as (4) with Hygromycin removed subsequently (pDR2-sense-Alu; Hygromycin added→removed, week 1); and (6) the original HEK 293 cells (no treatment). Vertical bars, means of expression levels per various gene sets from triplicate experiments. Error bars, standard deviations. (B) GSEA plots for the suppression effects of Ant-alus (upper left) and Sens-alus (upper right) in response to antisense Alu transfections, as well as sense Alu transfections (lower left and right respectively). NES, Normalized enrichment score. (C) The heatmap of a collection of Ant-alu genes which showed significant suppression individually upon sense Alu transfection, using cells transfected by empty vectors as controls (P< 0.0005, FDR < 0.0321). Green color indicated suppression. (D) The heatmap of a collection of Sens-alu genes which showed significant suppression upon antiense Alus transfection (P< 0.0005, FDR < 0.0518). (E) A heatmap representation of protein expressions of randomly selected Ant-alu genes, quantified at different time points by western blotting, up to the 8th week after the removal of Hygromycin. Protein levels of cells transfected by empty vectors (pDR2) were presented as baselines. Numbers in the time axis indicated weeks after Hygromycin removal. The time-course profile of extrachromosomal expression of sense Alu RNA was also presented. (F) Protein levels of randomly selected Sens-alu genes quantified at different time points. The time-course profile of exogeneous antisense Alu RNA was presented.
Figure 3Gene activations and suppressions mediated by Alu-carrying RNAs. (A) A conceptual interaction network, where any two RNA species that may form a long (280~300 bp) Alu duplex were depicted by mutual inhibition signs. Central to the regulation network are Ant-alus and Sens-alus, which together represent 7.3% of total protein-coding genes. Their RNA levels may affect downstream protein levels. Pol III derived Alus may also form a binding with Ant-alus, enabling a mutual regulation. A few non-coding RNAs (ncRNAs) have also been reported elsewhere to bind with Sens-alus and then trigger STAU1-mediated mRNA decay. (B) The activation restriction model. A set of alu-carrying genes was activated and increased expression level in response to outside stimulation. The elevation of these genes increased the Alu element in the cytosol, which can suppress the activation of other Alu-carrying genes which are associated to other pathways. The suppression will continue until the original signal has subsided. Then a new activation can proceed. (C) Waves of genes are activated coordinately, with different set of genes activated in different time, due to Alu-mediated suppression.